527MO Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study

Autor:	R. Kristeleit, S. Ghamande, M-C. Lim, C. Parkinson, M. Morgan, M. Wilson, A. Oaknin, J. Buscema, P. Bessette, D. Lorusso, F. Ueland, T. Safra, J. Barlin, F. Marmé, T.J. Herzog, I. McNeish, S. Goble, S. Hume, K. Fujiwara, B.J. Monk
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S786-S787
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2022.07.655
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::770e532ae147619d7f7aa2e6d05487f6 https://doi.org/10.1016/j.annonc.2022.07.655 Zobrazit plný text záznamu